[Edaily Reporter YU JIN-HEE ] KOSDAQ-listed company KMPHARMACEUTICAL Co.,Ltd.(225430), which has recently faced internal turmoil following its designation as a “monitored stock,” has released a Seohan signed by its CEO. The company disclosed to shareholders, in detail and with full transparency, an aggressive financial restructuring plan—including a capital increase funded by the largest shareholder’s personal assets—and expressed its commitment to swiftly restore corporate value to a healthy trajectory through responsible management.

Through a Seohan personally written by CEO Baek Seung-won, KMPHARMACEUTICAL Co.,Ltd. announced its specific future management direction and comprehensive plans to enhance corporate value—aimed at resolving its “monitored stock” designation—via a regulatory filing and its official website on the 15th.

At the beginning of the Seohan, he bowed his head in apology, stating, “As CEO, I deeply feel the weight of responsibility for causing great concern to our shareholders due to the recent designation as a ‘monitored stock.’”

He continued, “I fully recognize the gravity of the situation we currently face,” and declared, “We will make the early resolution of the ‘monitored stock’ designation and the restoration of shareholder value our top management priorities for this year and will concentrate the company’s full resources on these goals.”

This Seohan outlines a concrete action plan to swiftly improve the company’s fundamentals. The key points include: △ Conducting a 1 billion won third-party private placement through the CEO’s contribution of personal funds; △ Proactively improving the financial structure by restructuring held assets; △ Upgrading production facilities and expanding investment in research and development (R&D); and △ Maximizing competitiveness in the original equipment manufacturer (OEM) and original design manufacturer (ODM) businesses.

The company explained that CEO Baek’s direct participation in this capital increase is a measure intended to dispel unnecessary market concerns. It is viewed as a decisive move that goes beyond the simple purpose of raising corporate funds, demonstrating through action the CEO’s firm confidence in the company’s future growth potential and value recovery.

The new funds raised through the capital increase will be invested in enhancing financial soundness and securing future growth engines. KMPHARMACEUTICAL Co.,Ltd. plans to significantly reduce its debt-to-equity ratio and stabilize its financial structure by repaying loans. At the same time, building on its core strength—manufacturing competitiveness—the company plans to focus on establishing next-generation production facilities and developing high-value-added new products. The company also intends to rapidly regain its dominance in the OEM and ODM markets by implementing a tight, profitability-focused sales strategy.

CEO Baek’s sincere efforts to communicate with the market and shareholders to restore their trust are also drawing attention. In his Seohan, CEO Baek promised, “We will not become a company that engages in one-sided public relations by selectively sharing only good news,” adding, “I will honestly and openly share with our shareholders the progress we make in improving management—whether it’s positive or, even if we face obstacles and results are lackluster, the reality of the situation.”

A KMPHARMACEUTICAL Co.,Ltd. official emphasized, “Since the Seohan was made public, we have been seeing positive reactions from shareholders—particularly on our official website and investor communities—who appreciate the CEO’s sincere commitment to responsible management,” adding, “All employees will give it their all to prove these promises through actual business performance and results.”